They seem like pretty fair responses...In your next email can...

First 98 Last

Share
Profile

Follow
Titans19

2,915 Posts.

1294

08/11/21

14:25

Post #: 57398881
Share

Originally posted by JabraD: ↑

cleared up with Tom, thought Id share:

Running another Phase 2 study is unnecessary and will delay things because we know this drug lowers ICP (as it follows the science) and moreover, the regulator (EMA) was ok with a single Phase 3 to register this drug. Running a 100 patient Phase 2 over the next say 2+ years would only re-confirm what we’ve done and not have the statistical power to show a difference in those clinical measures. So it would be a waste of time and money. As we spoke about, we are fully funded to complete, report and file Presendin for approval in these markets. If it fails, we would still retain sufficient funds to consider next steps. Unfortunately, this is biotech – we need to spend the money to find the answer(s). If it works, the payback is enormous, naturally.
An interim analysis will significantly compromise the final analysis and the strong advice from study statisticians was to not consider it.

Interim analyses introduce the chance of falsely rejecting the null hypothesis. In other words, every time you look at the data there is a chance of a type 1 error (false positive). Also the medical fraternity will likely frown on interim analysis ahead of the final planned results.

Interim analyses are more common in diseases like cancer where the intervention may be very effective, and because there is a risk of dying of progressive disease, may be unethical to not offer the intervention to the control arm. In Invex’s case, the treatment period is relatively short (24 weeks) and IIH does not pose a significant risk of death

Expand

They seem like pretty fair responses...

In your next email can you ask what their opinion of the share price is? Being this low going into a fully funded Phase 3 trial is ridiculous!

Ask for the opinion on why this may be the case? Not enough exposure to retail market? Not a headline condition?.. And what they plan to do for current holders over the next 12+ months while the trial is in progress?

If it doesn't jump soon, there is no incentive to hold when money can be made elsewhere (or sheds built...)

Cheers

IXC Price at posting: 66.0¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

STX

Strike Energy wins EPA green tick for West Erregulla; AGIG also awarded pipeline licence

TLS

Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago

EM2

Eagle Mountain unlocks porphyry Cu targets at Arizona play

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 71 more messages in this thread...

First 98 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 6.7¢		Change 0.000(0.00%)		Mkt cap ! $5.035M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	147614	6.6¢

Sellers (Offers)

Price($)	Vol.	No.
7.4¢	5400	1

View Market Depth

No.	Vol.	Price($)
2	147614	0.066
1	100000	0.052
1	400000	0.051
1	60001	0.041
1	500000	0.040

Price($)	Vol.	No.
0.074	5400	1
0.075	10000	1
0.083	4000	1
0.085	1000	1
0.090	131356	2

Last trade - 10.04am 09/07/2024 (20 minute delay)

IXC (ASX) Chart

Day chart unavailable

They seem like pretty fair responses...In your next email can...

Strike Energy wins EPA green tick for West Erregulla; AGIG also awarded pipeline licence

Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago

Eagle Mountain unlocks porphyry Cu targets at Arizona play

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

They seem like pretty fair responses...In your next email can...

Top Stories

Strike Energy wins EPA green tick for West Erregulla; AGIG also awarded pipeline licence

Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago

Eagle Mountain unlocks porphyry Cu targets at Arizona play

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News